Publication | Open Access
<i>HER2</i> and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial
231
Citations
34
References
2010
Year
These results confirm that IHC or FISH HER2 testing is appropriate for patient selection for adjuvant trastuzumab therapy. Trastuzumab benefit seemed independent of HER2/centromere 17 ratio and chromosome 17 copy number.
| Year | Citations | |
|---|---|---|
Page 1
Page 1